Novo Nordisk said in its news release that participants in the trial who were obese and who took semaglutide 25 mg the once-daily pill of its injectable Wegovy lost an average 16% of their body weight if they followed the treatment as directed, compared with a placebo group that lost 2.7%
The customer service has generated serious complaints
Full appetite suppression builds progressively as the dose escalates every 4 weeks
Apply light pressure for a few seconds, but avoid rubbing the area, as this can cause irritation
Nevertheless, individual patient factorssuch as other medical conditions, additional medications, and personal tolerancemust be carefully considered
Currently, a BMI of 40 is required for obese recipients and 27 for those with diabetes